A $5 billion Silicon Valley VC is getting back into biotech and looking to back ‘iconic entrepreneurs’ – Business Insider
Business Insider |
A $5 billion Silicon Valley VC is getting back into biotech and looking to back ‘iconic entrepreneurs’
Business Insider Specifically, the plan will be to invest in companies that are in diagnostics, genomics, digital health, synthetic biology, and have a data-driven platforms for drug discovery. So far, Menlo has invested in Synthego, Cofactor Genomics, Clear Labs … Menlo Ventures banks on tech-driven life sciences, adds Greg Yap as new partnerVentureBeat Menlo Ventures adds Greg Yap as Partner to Focus on Life Science Technology InvestingGlobeNewswire (press release) |
The Verge |
Scientists used human stem cells to build a new rat intestine
The Verge Scientists have built a new rat intestine by combining part of the animal’s own bowel with human stem cells. One day, this method could be used in humans with intestinal problems who currently have to rely on organ transplants. A variety of diseases, … Team creates functional, stem–cell-derived small bowel segmentsMedical Xpress Human intestines have been grown in a lab and transplanted into rats – paving the way to a cure for gut disordersDaily Mail |
Scientific American |
Gene Therapy for Blindness Appears Initially Effective, Says US FDA
Scientific American (Reuters) – Spark Therapeutics Inc’s experimental gene therapy for a rare inherited form of blindness is effective, though it is unclear whether the benefit lasts over time, according to a preliminary review by the U.S. Food and Drug Administration … Seeing hope: FDA panel considers gene therapy for blindnessABC News The FDA could soon approve gene therapy for blindnessThe Week Magazine With AdComm meeting looming, FDA shares concerns about Spark’s lead gene therapyFierceBiotech Press Herald –Endpoints News all 19 news articles » |
Simply Wall St |
Why CRISPR Therapeutics AG Stock Lost Ground in September
Motley Fool According to data from S&P Global Market Intelligence, shares of the gene-editing company CRISPR Therapeutics (NASDAQ:CRSP) dropped by 13.1% in September. CRISPR’s poor showing last month appears to stem from nothing more than investors … Next Capital Raising For CRISPR Therapeutics AG (CRSP)?Simply Wall St Street Analysts View On CRISPR Therapeutics AG (CRSP), China Life Insurance Company Limited (LFC)Post Analyst Crispr Therapeutics AG (CRSP) Expected to Announce Earnings of -$0.49 Per ShareBangaloreWeekly Highlight Press –Hot Stocks Point all 11 news articles » |